Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokineticsof the active components of anextrafineformulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G)delivered via a hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI) in Chinese healthy adults

Trial Profile

Pharmacokineticsof the active components of anextrafineformulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G)delivered via a hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI) in Chinese healthy adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 02 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top